Repligen Co. (NASDAQ:RGEN) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC raised its holdings in Repligen Co. (NASDAQ:RGEN – Get Rating) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,307 shares of the biotechnology company’s stock after acquiring an additional 595 shares during the quarter. HighTower Advisors LLC’s holdings in Repligen were worth $3,116,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Thrivent Financial for Lutherans increased its position in shares of Repligen by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 177,458 shares of the biotechnology company’s stock valued at $30,046,000 after buying an additional 2,491 shares in the last quarter. Credit Suisse AG increased its position in shares of Repligen by 1.5% in the third quarter. Credit Suisse AG now owns 52,577 shares of the biotechnology company’s stock valued at $9,837,000 after buying an additional 758 shares in the last quarter. Amalgamated Bank increased its position in shares of Repligen by 3.6% in the third quarter. Amalgamated Bank now owns 39,981 shares of the biotechnology company’s stock valued at $7,481,000 after buying an additional 1,395 shares in the last quarter. Congress Wealth Management LLC DE increased its position in shares of Repligen by 20.2% in the third quarter. Congress Wealth Management LLC DE now owns 7,042 shares of the biotechnology company’s stock valued at $1,318,000 after buying an additional 1,185 shares in the last quarter. Finally, MML Investors Services LLC increased its position in shares of Repligen by 14.8% in the third quarter. MML Investors Services LLC now owns 11,061 shares of the biotechnology company’s stock valued at $2,070,000 after buying an additional 1,429 shares in the last quarter. Hedge funds and other institutional investors own 91.00% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $159.25 on Monday. The firm has a market capitalization of $8.87 billion, a P/E ratio of 53.98, a P/E/G ratio of 2.81 and a beta of 1.08. Repligen Co. has a 1-year low of $137.65 and a 1-year high of $262.26. The business’s 50-day simple moving average is $163.39 and its 200-day simple moving average is $173.11.

Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $182.70 million during the quarter, compared to analysts’ expectations of $181.43 million. Repligen had a return on equity of 9.14% and a net margin of 21.58%. Repligen’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.92 EPS. On average, equities research analysts expect that Repligen Co. will post 2.37 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Stifel Nicolaus dropped their price objective on Repligen from $225.00 to $210.00 in a research report on Wednesday, May 3rd. Craig Hallum dropped their price objective on Repligen from $220.00 to $207.00 in a research report on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft dropped their price objective on Repligen from $180.00 to $165.00 in a research report on Wednesday, May 3rd. Royal Bank of Canada dropped their price objective on Repligen from $170.00 to $157.00 in a research report on Wednesday, May 3rd. Finally, Benchmark dropped their price objective on Repligen from $230.00 to $210.00 in a research report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $208.56.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus bought 500 shares of the business’s stock in a transaction on Monday, May 8th. The shares were bought at an average cost of $156.18 per share, with a total value of $78,090.00. Following the transaction, the director now directly owns 1,611 shares in the company, valued at approximately $251,605.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.10% of the stock is owned by company insiders.

Repligen Company Profile

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.